Immune-mediated cholangitis: is it always nivolumab's fault?

Cancer Immunol Immunother. 2018 Aug;67(8):1325-1327. doi: 10.1007/s00262-018-2159-3. Epub 2018 Apr 5.

Authors

Francesco Gelsomino¹, Giovanni Vitale², Andrea Ardizzoni²

Affiliations

¹ Medical Oncology Unit, Policlinico S. Orsola-Malpighi, University of Bologna, Via Albertoni 15, 40138, Bologna, Italy. [email protected].
² Medical Oncology Unit, Policlinico S. Orsola-Malpighi, University of Bologna, Via Albertoni 15, 40138, Bologna, Italy.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Autoimmune Diseases / chemically induced
Autoimmune Diseases / immunology*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Cholangitis / chemically induced
Cholangitis / immunology*
Humans
Lung Neoplasms / drug therapy*
Middle Aged
Nivolumab / adverse effects*
Prognosis

Substances

Antineoplastic Agents, Immunological
Nivolumab